



US006001844A

# United States Patent [19]

Bakshi et al.

[11] Patent Number: 6,001,844  
[45] Date of Patent: Dec. 14, 1999

## [54] 4-AZASTEROIDS FOR TREATMENT OF HYPERANDROGENIC CONDITIONS

[75] Inventors: Raman K. Bakshi, Edison; Soumya P. Sahoo, Old Bridge; Richard L. Tolman, Warren, all of N.J.

[73] Assignee: Merck & Co., Inc., Rahway, N.J.

[21] Appl. No.: 09/029,926

[22] PCT Filed: Sep. 11, 1996

[86] PCT No.: PCT/US96/14564

§ 371 Date: Mar. 11, 1998

§ 102(c) Date: Mar. 11, 1998

[87] PCT Pub. No.: WO97/10217

PCT Pub. Date: Mar. 20, 1997

### Related U.S. Application Data

[60] Provisional application No. 60/003,826, Sep. 15, 1995.

[51] Int. Cl.<sup>6</sup> ..... C07D 221/02; A61K 31/435

[52] U.S. Cl. .... 514/284; 514/255; 514/256; 514/262; 514/265; 514/266; 514/269; 514/272; 514/274; 514/275; 544/265; 544/269; 544/268; 544/276; 544/277; 544/301; 544/311; 544/312; 544/316; 544/317; 544/319; 544/320; 544/322; 544/323; 544/329; 544/332

[58] Field of Search ..... 514/255, 256, 514/262, 265, 266, 269, 272, 274, 275, 284; 544/265, 266, 268, 276, 277, 301, 311, 312, 316, 317, 319, 320, 322, 323, 329, 332, 334, 335, 336, 408, 409; 546/77

### References Cited

#### U.S. PATENT DOCUMENTS

4,191,759 3/1980 Johnston ..... 424/242  
4,377,584 3/1983 Rasmussen et al. .... 424/258  
4,760,071 7/1988 Rasmussen et al. .... 514/284  
5,116,983 5/1992 Bhattacharya ..... 546/14  
5,151,429 9/1992 Rasmussen ..... 514/284  
5,302,621 4/1994 Kojima et al. .... 514/284  
5,304,562 4/1994 Biollaz ..... 514/284  
5,565,467 10/1996 Baichlor et al. .... 514/284

#### FOREIGN PATENT DOCUMENTS

0 484 064 6/1992 European Pat. Off. .  
0 538 192 4/1993 European Pat. Off. .  
WO 92/16213 10/1992 WIPO .  
WO 94/07861 4/1994 WIPO .  
WO 95/07926 3/1995 WIPO .

WO 95/07927 3/1995 WIPO .

### OTHER PUBLICATIONS


Bakshi et al., 4-aza-3-oxo-5a-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5a-reductases. *J. Med. Chem.* 38 (1995), pp. 3189-3192.

Tolman et al., "4-Methyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-N-aryl-carboxamides: An approach to combined androgen blockade"; Mar. 1997 issue of *J. Steroid Biochem & Molec. Bio.* vol. 60, No. 5-6 pp. 303-309.

Primary Examiner—Mukund J. Shah  
Assistant Examiner—Brenda Coleman  
Attorney, Agent, or Firm—Philippe L. Durette; Catherine D. Fitch; Melvin Winokur

### [57] ABSTRACT

Compounds of structural Formula (I)



(I)

and pharmacologically acceptable salts and esters thereof possess 5α-reductase inhibitory activity. These compounds inhibit 5α-reductase type 1 and type 2. The compounds of structural Formula I are useful in the systemic, including oral, and parenteral, including topical, treatment and prevention of hyperandrogenic conditions including prostatic carcinoma, benign prostatic hyperplasia, acne vulgaris, seborrhea, androgenic alopecia (also called androgenetic alopecia) which includes male- and female-pattern baldness, female hirsutism, and prostatitis. A class of compounds of the present invention are also potent antiandrogens. The present invention also relates to novel compositions containing such compounds, methods of their use and methods of their manufacture.

13 Claims, No Drawings